GB0412530D0 - Formulation - Google Patents

Formulation

Info

Publication number
GB0412530D0
GB0412530D0 GB0412530A GB0412530A GB0412530D0 GB 0412530 D0 GB0412530 D0 GB 0412530D0 GB 0412530 A GB0412530 A GB 0412530A GB 0412530 A GB0412530 A GB 0412530A GB 0412530 D0 GB0412530 D0 GB 0412530D0
Authority
GB
United Kingdom
Prior art keywords
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0412530A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Camurus AB
Original Assignee
Camurus AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Camurus AB filed Critical Camurus AB
Priority to GB0412530A priority Critical patent/GB0412530D0/en
Publication of GB0412530D0 publication Critical patent/GB0412530D0/en
Priority to AU2005249274A priority patent/AU2005249274B2/en
Priority to ZA200700039A priority patent/ZA200700039B/en
Priority to RU2006146009/15A priority patent/RU2390331C2/en
Priority to ES05749850T priority patent/ES2309766T3/en
Priority to SG2011047453A priority patent/SG173326A1/en
Priority to CN2010102495161A priority patent/CN102008728B/en
Priority to DK05749850T priority patent/DK1768650T3/en
Priority to CN200580021940.8A priority patent/CN101014319B/en
Priority to CA2569513A priority patent/CA2569513C/en
Priority to AT05749850T priority patent/ATE401054T1/en
Priority to BRPI0511807A priority patent/BRPI0511807C8/en
Priority to US11/628,007 priority patent/US8236292B2/en
Priority to NZ551990A priority patent/NZ551990A/en
Priority to MXPA06014095A priority patent/MXPA06014095A/en
Priority to KR1020077000258A priority patent/KR101225257B1/en
Priority to PL05749850T priority patent/PL1768650T3/en
Priority to EP05749850A priority patent/EP1768650B1/en
Priority to DE602005008247T priority patent/DE602005008247D1/en
Priority to PCT/GB2005/002217 priority patent/WO2005117830A1/en
Priority to JP2007514136A priority patent/JP5127449B2/en
Priority to IL179815A priority patent/IL179815A/en
Priority to US11/798,495 priority patent/US8236755B2/en
Priority to AU2010202794A priority patent/AU2010202794B2/en
Priority to US13/537,096 priority patent/US8545832B2/en
Priority to US13/558,463 priority patent/US20130190341A1/en
Priority to US14/017,823 priority patent/US20140193347A1/en
Priority to US14/486,035 priority patent/US20150064118A1/en
Priority to US16/030,697 priority patent/US20180311163A1/en
Priority to US16/947,934 priority patent/US20210128473A1/en
Priority to US17/731,534 priority patent/US20230027339A1/en
Ceased legal-status Critical Current

Links

GB0412530A 2004-06-04 2004-06-04 Formulation Ceased GB0412530D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GB0412530A GB0412530D0 (en) 2004-06-04 2004-06-04 Formulation
US11/628,007 US8236292B2 (en) 2004-06-04 2005-06-06 Liquid depot formulations
MXPA06014095A MXPA06014095A (en) 2004-06-04 2005-06-06 Liquid depot formulations.
EP05749850A EP1768650B1 (en) 2004-06-04 2005-06-06 Liquid depot formulations
KR1020077000258A KR101225257B1 (en) 2004-06-04 2005-06-06 Liquid depot formulation
ES05749850T ES2309766T3 (en) 2004-06-04 2005-06-06 SLOW RELEASE LIQUID FORMULATIONS.
SG2011047453A SG173326A1 (en) 2004-06-04 2005-06-06 Liquid depot formulations
CN2010102495161A CN102008728B (en) 2004-06-04 2005-06-06 Liquid depot formulations
DK05749850T DK1768650T3 (en) 2004-06-04 2005-06-06 Liquid storage formulations
CN200580021940.8A CN101014319B (en) 2004-06-04 2005-06-06 Liquid depot formulation
CA2569513A CA2569513C (en) 2004-06-04 2005-06-06 Preformulation for liquid crystalline phase structure
AT05749850T ATE401054T1 (en) 2004-06-04 2005-06-06 LIQUID DEPOSIT FORMULATIONS
BRPI0511807A BRPI0511807C8 (en) 2004-06-04 2005-06-06 preformulation, process of forming a preformulation and use thereof
ZA200700039A ZA200700039B (en) 2004-06-04 2005-06-06 Liquid depot formulations
NZ551990A NZ551990A (en) 2004-06-04 2005-06-06 Liquid depot formulations
AU2005249274A AU2005249274B2 (en) 2004-06-04 2005-06-06 Liquid depot formulations
RU2006146009/15A RU2390331C2 (en) 2004-06-04 2005-06-06 Liquid drug reservoirs
PL05749850T PL1768650T3 (en) 2004-06-04 2005-06-06 Liquid depot formulations
JP2007514136A JP5127449B2 (en) 2004-06-04 2005-06-06 Fluid depot formulation
DE602005008247T DE602005008247D1 (en) 2004-06-04 2005-06-06 LIQUID DEPOT FORMULATIONS
PCT/GB2005/002217 WO2005117830A1 (en) 2004-06-04 2005-06-06 Liquid depot formulations
IL179815A IL179815A (en) 2004-06-04 2006-12-04 Liquid pre-formulations comprising a low viscosity non-liquid crystalline mixture, formulations and use thereof
US11/798,495 US8236755B2 (en) 2004-06-04 2007-05-14 Opioid depot formulations
AU2010202794A AU2010202794B2 (en) 2004-06-04 2010-07-01 Liquid depot formulations
US13/537,096 US8545832B2 (en) 2004-06-04 2012-06-29 Lipid depot formulations
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US14/017,823 US20140193347A1 (en) 2004-06-04 2013-09-04 Lipid depot formulations
US14/486,035 US20150064118A1 (en) 2004-06-04 2014-09-15 Lipid depot formulations
US16/030,697 US20180311163A1 (en) 2004-06-04 2018-07-09 Lipid depot formulations
US16/947,934 US20210128473A1 (en) 2004-06-04 2020-08-25 Lipid depot formulations
US17/731,534 US20230027339A1 (en) 2004-06-04 2022-04-28 Lipid depot formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0412530A GB0412530D0 (en) 2004-06-04 2004-06-04 Formulation

Publications (1)

Publication Number Publication Date
GB0412530D0 true GB0412530D0 (en) 2004-07-07

Family

ID=32696694

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0412530A Ceased GB0412530D0 (en) 2004-06-04 2004-06-04 Formulation

Country Status (3)

Country Link
CN (1) CN101014319B (en)
GB (1) GB0412530D0 (en)
ZA (1) ZA200700039B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130236448A1 (en) * 2009-08-04 2013-09-12 F. Hoffmann-La Roche Ag (Roche Glycart Ag) Concentrated polypeptide formulations with reduced viscosity
EP4427814A2 (en) * 2011-05-25 2024-09-11 Camurus AB Controlled release peptide formulations
WO2013115201A1 (en) * 2012-01-31 2013-08-08 参天製薬株式会社 Non-aqueous liquid composition
US9937164B2 (en) 2012-07-26 2018-04-10 Camurus Ab Opioid formulations
KR101586790B1 (en) * 2012-12-28 2016-01-19 주식회사 종근당 Sustained-release lipid pre-concentrate of anionic pharmacologically active substances and pharmaceutical composition comprising the same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
KR101809908B1 (en) * 2014-07-21 2018-01-25 주식회사 종근당 Pharmaceutical composition comprising 5-α reductase inhibitor
BR112017013471A2 (en) * 2014-12-23 2018-02-27 Camurus Ab PRE-FORMULATION, PHARMACEUTICAL FORMULATION, DEPOSIT COMPOSITION, METHODS FOR THE ADMINISTRATION OF A BIOACTIVE AGENT TO A HUMAN OR NON-HUMAN ORGANISM, FOR THE PREPARATION OF A LIQUID CRYSTALLINE COMPOSITION, FOR THE TREATMENT OR NUMBER OF AN INDIVIDUAL, AN INDIVIDUAL A PRE-FORMULATION FOR A SUBJECT WHO NEEDS IT, PROCESS FOR FORMING A PRE-FORMULATION, USE OF A NON-LIQUID CRYSTALLINE MIXTURE WITH LOW VISCOSITY, PRE-COMPLETED ADMINISTRATION DEVICE, AND, KIT.
GB201516554D0 (en) * 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
WO2018050864A1 (en) * 2016-09-15 2018-03-22 Camurus Ab Prostacyclin analogue formulations
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
AU2018370039A1 (en) * 2017-11-15 2020-05-21 Rhythm Pharmaceuticals, Inc. Sustained release peptide formulations
CN107998401B (en) * 2017-12-11 2021-06-18 广州立白企业集团有限公司 Oral cavity medicinal preparation with slow release effect and preparation method thereof
CN109091451B (en) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 Oil phase liquid crystal gel precursor preparation of hydrophilic medicine and preparation method thereof
CN111388744B (en) * 2020-01-15 2021-05-18 华中科技大学 Gel storage, preparation method thereof and application of gel storage in preparation of postoperative hemostatic preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE518578C2 (en) * 1994-06-15 2002-10-29 Gs Dev Ab Lipid-based composition
BE1011899A6 (en) * 1998-04-30 2000-02-01 Ucb Sa PHARMACEUTICAL USE gelling.

Also Published As

Publication number Publication date
CN101014319A (en) 2007-08-08
CN101014319B (en) 2013-03-27
ZA200700039B (en) 2008-06-25

Similar Documents

Publication Publication Date Title
ZA200801773B (en) New formulation
TWI370115B (en) New formulation
AP2006003810A0 (en) 4-Phenylamino-quinazolin-6-yl-amides
GB0423565D0 (en) Formulation
GB0412530D0 (en) Formulation
GB0526419D0 (en) Formulation
GB0418540D0 (en) Use
GB0414895D0 (en) Herbicidal formulation
GB0517673D0 (en) Formulation
EP1712218A4 (en) Hairdye preparation
LT1928232T (en) Solid formulation
GB0407301D0 (en) Use
GB0410015D0 (en) Use
GB0501030D0 (en) Formulation
GB0506035D0 (en) Improved formulation
GB0412878D0 (en) Use
GB0401114D0 (en) Formulation
GB0426142D0 (en) Formulation
GB0407958D0 (en) Formulation
GB0408112D0 (en) Improved formulation
GB0409129D0 (en) New formulation
GB0412412D0 (en) New formulation
GB0424494D0 (en) Use
GB0419025D0 (en) Boardgame
GB0500807D0 (en) Formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)